Spironolactone

證據等級: L5

預測適應症: 2 個

One-Sentence Summary

Spironolactone is a mineralocorticoid (aldosterone) receptor antagonist historically used for conditions such as edema and hypertension, and off-label for androgenetic alopecia due to its anti-androgenic activity. The TxGNN model predicts it may be effective for Hypotrichosis Simplex of the Scalp, a hereditary hair-loss disorder, but this prediction is currently supported by 0 clinical trials and 0 publications — evidence level L5 (model prediction only).

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (data gap); spironolactone is generally known as an aldosterone antagonist used for edema/fluid retention and hypertension
Predicted New Indication	Hypotrichosis simplex of the scalp
TxGNN Prediction Score	99.26%
Evidence Level	L5
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on generally known pharmacology, spironolactone is a mineralocorticoid receptor antagonist that also exhibits anti-androgenic activity, which is why it is used off-label for androgenetic alopecia (a hormone/androgen-driven hair loss condition).

However, hypotrichosis simplex of the scalp is a hereditary, autosomal condition most often linked to APCDD1 mutations that disrupt the Wnt signaling pathway required for normal hair follicle development. This mechanism is unrelated to androgen or mineralocorticoid signaling. As a result, there is no established biological pathway connecting spironolactone's known pharmacology to this specific genetic disorder — the high TxGNN score (0.99) most likely reflects embedding similarity between "hair loss" phenotypes in the model's knowledge graph rather than a genuine causal or mechanistic link.

A second candidate in this evidence pack, congenital hypotrichosis with milia (score 0.99, rank 9732), shows the same pattern: it is a rare ectodermal dysplasia driven by keratinocyte differentiation/follicle development genes, with no known relationship to mineralocorticoid or androgen pathways. Both predictions should be treated as hypothesis-generating only, not as evidence of therapeutic plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Germany Market Information

Spironolactone is currently not marketed in Germany under this evidence pack (0 authorizations on file), so no license table can be produced.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/label-level warnings, contraindications, and drug-drug interaction data are currently unavailable — this is a blocking data gap (DG001) that must be resolved before any safety evaluation (S1) can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication has no clinical trial or literature support (L5, decision stage S0), and the proposed mechanistic link between spironolactone's known pharmacology and this hereditary Wnt-pathway hair disorder is not biologically supported. In addition, safety labeling data (warnings/contraindications) is missing, which blocks any safety pre-assessment.

To proceed, the following is needed:

TFDA/EMA label warnings and contraindications (DG001, blocking — required before S1 safety screening)
Verified original indication and mechanism of action data from DrugBank (DG002)
Any preclinical or genetic evidence linking mineralocorticoid/anti-androgen activity to APCDD1/Wnt-pathway hair follicle disorders
If no such mechanistic or empirical evidence can be found, this candidate should remain at S0/Hold indefinitely rather than advance on TxGNN score alone
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.